TY  - EJOU
AU  - TIAN, FEIFEI 
AU  - HU, AN 
AU  - WANG, DI 
AU  - DING, HUAN 
AU  - CHI, QINGJIA 
AU  - LIANG, HUAPING 
AU  - ZENG, WENLI 

TI  - Immune-related DNA methylation signature associated with APLN expression predicts prognostic of hepatocellular carcinoma
T2  - BIOCELL

PY  - 2022
VL  - 46
IS  - 10
SN  - 1667-5746

AB  - This study used transcriptome and epigenetic data to predict the prognosis of immune-related genes (IRGs) Apelin
(APLN) in patients with hepatocellular carcinoma (HCC). The TCGA database has gene expression and clinical data for HCC.
And DNA methylation 450 k data for HCC was download from the University of California Santa Cruz (UCSC) Xena
browser. Performing clinical and prognostic analysis of APLN expression, results show that APLN is highly expressed in
tumor samples. And it has an increasing trend with the development of clinical stage and T stage. To explore the
prognostic role of APLN, the Immune-related DNA methylation (DNAm) sites associated with APLN analyzed by
bioinformatics. Univariate COX screened the methylation sites that are related to both APLN and survival. The risk score
related to methylation site signature was determined according to their least absolute shrinkage and selection operator
(LASSO) coefficients. Then the patients were divided into high-risk groups and low-risk groups. Significant differences in
overall survival (OS) were found in the training cohort. Nomogram shows that APLN or methylation signature can
effectively predict the prognosis of HCC patients. In summary, APLN may be a diagnostic and prognostic marker for HCC.
KW  - TIME
KW  -  Immunity
KW  -  Prognosis
KW  -  Bioinformatics

DO  - 10.32604/biocell.2022.020198